New York State Common Retirement Fund increased its position in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 19.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,399 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,491 shares during the quarter. New York State Common Retirement Fund owned approximately 0.14% of Paratek Pharmaceuticals worth $950,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Legal & General Group Plc boosted its position in Paratek Pharmaceuticals by 13.3% during the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock worth $144,000 after acquiring an additional 687 shares during the last quarter. Wells Fargo & Company MN boosted its position in Paratek Pharmaceuticals by 9.9% during the first quarter. Wells Fargo & Company MN now owns 15,566 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,400 shares during the last quarter. ProShare Advisors LLC boosted its position in Paratek Pharmaceuticals by 14.1% during the second quarter. ProShare Advisors LLC now owns 16,191 shares of the specialty pharmaceutical company’s stock worth $390,000 after acquiring an additional 2,005 shares during the last quarter. Nationwide Fund Advisors boosted its position in Paratek Pharmaceuticals by 22.9% during the second quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock worth $322,000 after acquiring an additional 2,492 shares during the last quarter. Finally, American International Group Inc. boosted its position in Paratek Pharmaceuticals by 34.1% during the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after acquiring an additional 2,824 shares during the last quarter. Hedge funds and other institutional investors own 80.59% of the company’s stock.

Paratek Pharmaceuticals, Inc. (NASDAQ PRTK) opened at $22.40 on Friday. Paratek Pharmaceuticals, Inc. has a 1-year low of $10.37 and a 1-year high of $29.00. The company has a current ratio of 11.88, a quick ratio of 11.88 and a debt-to-equity ratio of 0.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million. equities research analysts expect that Paratek Pharmaceuticals, Inc. will post -3.53 EPS for the current year.

A number of analysts recently issued reports on PRTK shares. HC Wainwright raised their target price on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Monday, July 17th. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Guggenheim started coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $40.00.

TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Has $950,000 Position in Paratek Pharmaceuticals, Inc. (PRTK)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2017/11/05/new-york-state-common-retirement-fund-has-950000-position-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.